These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 29265175)

  • 21. Secukinumab re-initiation achieves regain of high response levels in patients who interrupt treatment for moderate to severe plaque psoriasis.
    Blauvelt A; Reich K; Warren RB; Szepietowski JC; Sigurgeirsson B; Tyring SK; Messina I; Bhosekar V; Oliver J; Papavassilis C; Frueh J; Langley RGB
    Br J Dermatol; 2017 Sep; 177(3):879-881. PubMed ID: 28498514
    [No Abstract]   [Full Text] [Related]  

  • 22. Secukinumab: a review in moderate to severe plaque psoriasis.
    Garnock-Jones KP
    Am J Clin Dermatol; 2015 Aug; 16(4):323-330. PubMed ID: 26202871
    [TBL] [Abstract][Full Text] [Related]  

  • 23. First case of secukinumab successful therapy in a very elderly psoriatic patient.
    Ricceri F; Pescitelli L; Lazzeri L; Di Cesare A; Prignano F
    Dermatol Ther; 2018 Sep; 31(5):e12668. PubMed ID: 30209856
    [No Abstract]   [Full Text] [Related]  

  • 24. Secukinumab for psoriasis in a patient with hepatitis B.
    Feaster B; Cline A; Feldman SR
    Dermatol Online J; 2018 Sep; 24(9):. PubMed ID: 30677838
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, exhibits minimal immunogenicity in patients with moderate-to-severe plaque psoriasis.
    Reich K; Blauvelt A; Armstrong A; Langley RG; Fox T; Huang J; Papavassilis C; Liang E; Lloyd P; Bruin G
    Br J Dermatol; 2017 Mar; 176(3):752-758. PubMed ID: 27518376
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Secukinumab for plaque psoriasis.
    Ordenes-Cavieres G; Andino-Navarrete R
    Medwave; 2018 Nov; 18(7):e7364. PubMed ID: 30507896
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term management of erythrodermic psoriasis with anti-TNF agents.
    Romero-Maté A; García-Donoso C; Martinez-Morán C; Hernández-Núñez A; Borbujo J
    Dermatol Online J; 2010 Jun; 16(6):15. PubMed ID: 20579470
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Secukinumab (AIN-457) for the treatment of Psoriasis.
    Jaleel T; Elmets C; Weinkle A; Kassira S; Elewski B
    Expert Rev Clin Pharmacol; 2016; 9(2):187-202. PubMed ID: 26647300
    [TBL] [Abstract][Full Text] [Related]  

  • 29. European S3-Guideline on the systemic treatment of psoriasis vulgaris - Update Apremilast and Secukinumab - EDF in cooperation with EADV and IPC.
    Nast A; Spuls PI; van der Kraaij G; Gisondi P; Paul C; Ormerod AD; Saiag P; Smith CH; Dauden E; de Jong EM; Feist E; Jobling R; Maccarone M; Mrowietz U; Papp KA; Reich K; Rosumeck S; Talme T; Thio HB; van de Kerkhof P; Werner RN; Dressler C
    J Eur Acad Dermatol Venereol; 2017 Dec; 31(12):1951-1963. PubMed ID: 28895202
    [No Abstract]   [Full Text] [Related]  

  • 30. No need to change the drug class: ixekizumab- following secukinumab-therapy in psoriasis.
    Bokor-Billmann T; Schäkel K
    J Dermatolog Treat; 2019 May; 30(3):216-220. PubMed ID: 30051725
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Complete response of secukinumab in palmoplantar psoriasis.
    Rocamora V; Garcías-Ladaria J
    Dermatol Online J; 2017 Oct; 23(10):. PubMed ID: 29469799
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Our experience with infliximab in reclacitrant cases of psoriasis].
    Pereiro M; González-Vilas D; Sánchez-Aguilar D; Toribio J
    Actas Dermosifiliogr; 2008 Jul; 99 Suppl 4():43-7. PubMed ID: 19080991
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effectiveness and safety of secukinumab in 69 patients with moderate to severe plaque psoriasis: A retrospective multicenter study.
    Schwensen JF; Clemmensen A; Sand C; Gniadecki R; Skov L; Zachariae C; Iversen L; Rasmussen M; Thomsen SF
    Dermatol Ther; 2017 Nov; 30(6):. PubMed ID: 28906051
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Secukinumab treatment of moderate to severe plaque psoriasis in routine clinical care: real-life data of prior and concomitant use of psoriasis treatments from the PROSPECT study.
    Körber A; Thaçi D; von Kiedrowski R; Bachhuber T; Melzer N; Kasparek T; Kraehn-Senftleben G; Amon U; Augustin M
    J Eur Acad Dermatol Venereol; 2018 Mar; 32(3):411-419. PubMed ID: 28960469
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical and economic review of secukinumab for moderate-to-severe plaque psoriasis.
    Wong IT; Shojania K; Dutz J; Tsao NW
    Expert Rev Pharmacoecon Outcomes Res; 2016; 16(2):153-66. PubMed ID: 26681527
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The impact of secukinumab treatment on the prevalence of human papillomavirus in patients with psoriasis: A pilot study.
    Chiu HY; Tsai TF
    J Am Acad Dermatol; 2016 Jul; 75(1):224-6. PubMed ID: 27317524
    [No Abstract]   [Full Text] [Related]  

  • 37. Secukinumab shows significant efficacy in palmoplantar psoriasis: Results from GESTURE, a randomized controlled trial.
    Gottlieb A; Sullivan J; van Doorn M; Kubanov A; You R; Parneix A; Hugot S; Milutinovic M
    J Am Acad Dermatol; 2017 Jan; 76(1):70-80. PubMed ID: 27707593
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a 24-week, randomized, double-blind, placebo-controlled phase 3b study.
    Bagel J; Duffin KC; Moore A; Ferris LK; Siu K; Steadman J; Kianifard F; Nyirady J; Lebwohl M
    J Am Acad Dermatol; 2017 Oct; 77(4):667-674. PubMed ID: 28780364
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR study.
    Blauvelt A; Reich K; Tsai TF; Tyring S; Vanaclocha F; Kingo K; Ziv M; Pinter A; Vender R; Hugot S; You R; Milutinovic M; Thaçi D
    J Am Acad Dermatol; 2017 Jan; 76(1):60-69.e9. PubMed ID: 27663079
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Characteristics of patients receiving ustekinumab compared with secukinumab for treatment of moderate-to-severe plaque psoriasis - nationwide results from the DERMBIO registry.
    Egeberg A; Iversen L; Gniadecki R; Hvid L; Dam TN; Bryld LE; Skov L
    J Eur Acad Dermatol Venereol; 2017 Jul; 31(7):1183-1187. PubMed ID: 28273375
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.